Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Serce, Nuran Bektas ^a   Boesl, Andreas ^b   Klaman, Irina ^c   von Serényi, Sonja ^d   Noetzel, Erik ^d   Press, Michael F ^e   Dimmler, Arno ^f   Hartmann, Arndt ^g   Sehouli, Jalid ^h   Knuechel, Ruth ^d   Beckmann, Matthias W ^g   Fasching, Peter A ^g,i   Dahl, Edgar ^d  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b Department of Pathology   (Austria)

^c Signature Diagnostics AG   (Germany)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f St Vincentius Kliniken   (Germany)

^g UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Gene expression; Prognostic marker; SERBP1; UPA PAI 1

Indexed keywords

MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1 RNA BINDING PROTEIN; RNA BINDING PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; BREAST CELL; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOMA CELL; CELL LYSATE; COHORT ANALYSIS; CONTROLLED STUDY; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERBP1 GENE; TISSUE MICROARRAY; TISSUE SECTION; VALIDATION PROCESS; WESTERN BLOTTING;

BLOTTING, WESTERN; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KAPLAN-MEIER ESTIMATE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA-BINDING PROTEINS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84870912810     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-597     Document Type: Article

References (33)

1. Koensgen D, Mustea A, Klaman I, Sun P, Zafrakas M, Lichtenegger W, Denkert C, Dahl E, Sehouli J. Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression. Gynecol Oncol 2007, 107:266-273. 10.1016/j.ygyno.2007.06.023, 17698176.
2. Heaton JH, Dlakic WM, Dlakic M, Gelehrter TD. Identification and cDNA cloning of a novel RNA-binding protein that interacts with the cyclic nucleotide-responsive sequence in the Type-1 plasminogen activator inhibitor mRNA. J Biol Chem 2001, 276:3341-3347. 10.1074/jbc.M006538200, 11001948.
3. Heaton JH, Dlakic WM, Gelehrter TD. Posttranscriptional regulation of PAI-1 gene expression. Thromb Haemost 2003, 89:959-966. Review..
4. Lemos TA, Passos DO, Nery FC, Kobarg J. Characterization of a new family of proteins that interact with the C-terminal region of the chromatin-remodeling factor CHD-3. FEBS Lett 2003, 533:14-20.
5. Felsenfeld G. Chromatin as an essential part of the transcriptional mechanism. Nature 1992, 355:219-224. Review., 10.1038/355219a0, 1731219.
6. Peluso JJ, Romak J, Liu X. Progesterone receptor membrane component-1 (PGRMC1) is the mediator of progesterone's antiapoptotic action in spontaneously immortalized granulosa cells as revealed by PGRMC1 small interfering ribonucleic acid treatment and functional analysis of PGRMC1 mutations. Endocrinology 2008, 149:534-543. 2219306, 17991724.
7. Andreasen PA, Kjøller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997, 72:1-22. Review., 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z, 9212216.
8. Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, Ulm K, Höfler H, Jänicke F, Graeff H. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 1997, 78:285-296. Review..
9. Rosenberg S. The urokinase-type plasminogen activator system in cancer and other pathological conditions: introduction and perspective. Curr Pharm Des 2003, 9:4p. Review..
10. Zemzoum I, Kates RE, Ross JS, Dettmar P, Dutta M, Henrichs C, Yurdseven S, Höfler H, Kiechle M, Schmitt M, Harbeck N. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. J Clin Oncol 2003, 21:1022-1028. 10.1200/JCO.2003.04.170, 12637466.
11. Harbeck N, Thomssen C. 2003. Zentralbl Gynakol 2003, 125:362-367.
12. Kuhn W, Schmalfeldt B, Reuning U, Pache L, Berger U, Ulm K, Harbeck N, Späthe K, Dettmar P, Höfler H, Jänicke F, Schmitt M, Graeff H. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer 1999, 79:1746-1751. 10.1038/sj.bjc.6690278, 2362775, 10206287.
13. Tecimer C, Doering DL, Goldsmith LJ, Meyer JS, Abdulhay G, Wittliff JL. Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer. Int J Gynecol Cancer 2000, 10:372-381. 10.1046/j.1525-1438.2000.010005372.x, 11240701.
14. Dahl E, Kristiansen G, Gottlob K, Klaman I, Ebner E, Hinzmann B, Hermann K, Pilarsky C, Durst M, Klinkhammer-Schalke M, Blaszyk H, Knuechel R, Hartmann A, Rosenthal A, Wild PJ. Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer. Clin Cancer Res 2006, 12:3950-3960. 10.1158/1078-0432.CCR-05-2090, 16818692.
15. Bektas N, Noetzel E, Veeck J, Press MF, Kristiansen G, Naami A, Hartmann A, Dimmler A, Beckmann MW, Knüchel R, Fasching PA, Dahl E. The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer. Breast Cancer Res 2008, 10(4):R58. Epub 2008 Jul 15., 10.1186/bcr2117, 2575531, 18627608.
16. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410. 10.1111/j.1365-2559.1991.tb00229.x, 1757079.
17. Fasching PA, Loehberg CR, Strissel PL, Lux MP, Bani MR, Schrauder M, Geiler S, Ringleff K, Oeser S, Weihbrecht S, Schulz-Wendtland R, Hartmann A, Beckmann MW, Strick R. Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients. Breast Cancer Res Treat 2007,
18. Schrauder M, Frank S, Strissel PL, Lux MP, Bani MR, Rauh C, Sieber CC, Heusinger K, Hartmann A, Schulz-Wendtland R, Strick R, Beckmann MW, Fasching PA. Single nucleotide polymorphism D1853N of the ATM gene may alter the risk for breast cancer. J Cancer Res Clin Oncol 2008, 134:873-882. 10.1007/s00432-008-0355-9, 18264724.
19. Veeck J, Niederacher D, An H, Klopocki E, Wiesmann F, Betz B, Galm O, Camara O, Durst M, Kristiansen G, Huszka C, Knuchel R, Dahl E. Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene 2006, 25:3479-3488. 10.1038/sj.onc.1209386, 16449975.
20. Chekerov R, Klaman I, Zafrakas M, Könsgen D, Mustea A, Petschke B, Lichtenegger W, Sehouli J, Dahl E. Altered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy. Neoplasia 2006, 8:38-45. 10.1593/neo.05580, 1584288, 16533424.
21. Veeck J, Dahl E. RNA expression analysis on formalin-fixed paraffin-embedded tissues in TMA format by RNA in situ hybridization. Methods Mol Biol 2010, 664:135-150. 10.1007/978-1-60761-806-5_14, 20690060.
22. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987, 8:138-140.
23. Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A, Kiechle M, Jänicke F, Schmitt M, Foekens JA. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res 2002, 62(16):4617-4622.
24. Harbeck N, Kates RE, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 2002, 20(4):1000-1007. 10.1200/JCO.20.4.1000, 11844823.
25. Harbeck N, Thomssen C, Berger U, Ulm K, Kates RE, Höfler H, Jänicke F, Graeff H, Schmitt M. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse. Breast Cancer Res Treat 1999, 54(2):147-157. 10.1023/A:1006118828278, 10424405.
26. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC, American Society of Clinical Oncology American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25(33):5287-5312. 10.1200/JCO.2007.14.2364, 17954709, American Society of Clinical Oncology.
27. Sobin LH, Wittekind CH, UICC TNM Classification of Malignant Tumours 2002, New York: Wiley, 6, UICC.
28. Berger DH. Plasmin/plasminogen system in colorectal cancer. World J Surg 2002, 26:767-771. 10.1007/s00268-002-4050-8, 11965442.
29. Nekarda H, Siewert JR, Schmitt M, Ulm K. Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer. Lancet 1994, 343:117. 10.1016/S0140-6736(94)90845-1, 7903748.
30. Kobayashi H, Fujishiro S, Terao T. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res 1994, 54:6539-6548.
31. Lee YJ, Hsieh WY, Chen LY, Li C. Protein arginine methylation of SERBP1 by protein arginine methyltransferase 1 affects cytoplasmic/nuclear distribution. J Cell Biochem 2012, 113(8):2721-2728. 10.1002/jcb.24151, 22442049.
32. Lange CA, Yee D. Progesterone and breast cancer. Womens Health (Lond Engl) 2008, 4:151-162.
33. Lange CA, Sartorius CA, Abdel-Hafiz H, Spillman MA, Horwitz KB, Jacobsen BM. Progesterone receptor action: translating studies in breast cancer models to clinical insights. Adv Exp Med Biol 2008, 630:94-111. 10.1007/978-0-387-78818-0_7, 18637487.